DURATION OF DUAL ANTIPLATELET THERAPY: DEBATABLE QUESTIONS AND POSSIBLE SOLUTIONS


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The widespread use and high efficiency of minimally invasive coronary interventions, including coronary artery stenting, in various forms of coronary artery disease dictates the need to develop effective methods of prevention of stent thrombosis. This article discusses recent studies devoted to this issue, assessed the impact of dual antiplatelet therapy of varying duration on cardiovascular and hemorrhagic complications in patients with acute coronary syndrome and stable coronary artery disease. The problem of preferable choice and duration of therapy with antiplatelets is discussed

Full Text

Restricted Access

About the authors

Z. M Safiullina

SBEI HPE "Tyumen State Medical University" of RMPH

Email: safiullina@tokb.ru
MD, Prof. at the Department of Cardiology with the course Emergency Care Tyumen

L. A Salnikova

SBEI HPE "Tyumen State Medical University" of RMPH; Center for Heart and Vessels SBHCI of Tyumen region "Regional Clinical Hospital № 1

Tyumen

S. V Shalaev

SBEI HPE "Tyumen State Medical University" of RMPH; Center for Heart and Vessels SBHCI of Tyumen region "Regional Clinical Hospital № 1

Tyumen

References

  1. Joner M., Finn AV., Farb A., Mont E.K., Kolodgie F.D., Ladich E., Kutys R., Skorija K., Gold H.K., Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 2006;48(1):193-202
  2. Гиляревский Р. Проблема профилактики «позднего» тромбоза стентов с лекарственным покрытием: роль сочетанного применения антиагрегантной терапии. Сердце. 2007;6(5):23-8.
  3. Levine G.N., Bates E.R., Blankenship J.C., Bailey S.R., Bittl J.A., Cercek B., Chambers C.E., Ellis S.G., Guyton R.A., Hollenberg S.M., Khot U.N., Lange R.A., Mauri L., Mehran R., Moussa I.D., Mukherjee D., Nallamothu B.K., Ting H.H.; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions. 2011 ACCF/AHA/SCAI Guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol. 2011;58:e44-122.
  4. Roffi M., Patrono C., Collet JP, Mueller C., Valgimigli M., Andreotti F., Bax J.J., Borger M.A., Brotons C., Chew D.P., Gencer B., Hasenfuss G., Kjeldsen K., Lancellotti P., Landmesser U., Mehilli J., Mukherjee D., Storey R.F., Windecker S., Baumgartner H., Gaemperli O., Achenbach S., Agewall S., Badimon L., Baigent C., Bueno H., Bugiardini R., Carerj S., Casselman F., Cuisset T., Erol С, Fitzsimons D., Halle M., Hamm C., Hildick-SmithD,HuberK,IliodromitisE,JamesS.,LewisB.S, Lip G.Y., Piepoli M.F., Richter D., Rosemann T., Sechtem U., Steg P.G., Vrints C., Luis Zamorano J. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation. The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST segment elevation of the European Society of Cardiology. Eur. Heart J. 2016;37(3):267-315.
  5. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012;126:e354-e471.
  6. ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. http://eurheartj.oxfordjournals.org/content/ early/2013/08/28/eurheartj.eht
  7. ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2014. doi: 10.1093/eurheartj/ehu278
  8. Mauri L, Kereiakes D.J., Yeh R.W., Driscoll-Shempp P., Cutlip D.E., Steg P.G., Normand S.L., Braunwald E, Wiviott S.D., Cohen D.J., Holmes D.R. Jr, Krucoff M.W., Hermiller J., Dauerman H.L., Simon D.I., Kandzari D.E., Garratt K.N., Lee D.P., Pow T.K., Ver Lee P., Rinaldi M.J., Massaro J.M.; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N. Engl. J. Med. 2014;371(23):2155-66.
  9. Elmariah S., Mauri L., Doros G., Galper B.Z., O'Neill K.E., Steg P.G., Kereiakes D.J., Yeh R.W. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet. 2015. 385(9970):792-98.
  10. Valgimigli M., Tebaldi M., Borghesi M., Vranckx P., Campo G., Tumscitz C., Cangiano E., Minarelli M., Scalone A., Cavazza C., Marchesini J., Parrinello G.; PRODIGY Investigators. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY). JACC Cardiovasc. Interv. 2014;7(1):20-8.
  11. Campo G., Tebaldi M., Vranckx P., Biscaglia S., Tumscitz C., Ferrari R., Valgimigli M. Short- versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). J. Am. Coll. Cardiol. 2014;63(6):506-12.
  12. Valgimigli M., Borghesi M., Tebaldi M., Vranckx P., Parrinello G., Ferrari R. PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators. Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur. Heart J. 2013;34(12):909-19.
  13. Valgimigli M., Campo G., Monti M., Vranckx P., Percoco G., Tumscitz C., Castriota F., Colombo F., Tebaldi M., Fuca G., Kubbajeh M., Cangiano E., Minarelli M., Scalone A., Cavazza C., Frangione A., Borghesi M., Marchesini J., Parrinello G., Ferrari R. Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125(16):2015-26.
  14. Valgimigli M., Campo G., Percoco G., Monti M., Ferrari F., Tumscitz C., Zuffi A., Colombo F., Kubbajeh M., Cavazza C., Cangiano E., Tebaldi M., Minarelli M., Arcozzi C., Scalone A., Frangione A., Borghesi M., Marchesini J., Parrinello G., Ferrari R. Randomized comparison of 6- versus 24-month clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all-comer patients undergoing percutaneous coronary intervention Design and rationale for the PROlonging Dualantiplatelet treatment after Grading stent-induced Intimal hyperplasia study (PRODIGY). Am. Heart J. 2010;160(5):804-11.
  15. Sue Hughes. Questions Raised About Clopidogrel Duration Poststenting. Medscape. Aug 30, 2011.
  16. Palmerini T., Sangiorgi D., Valgimigli M., Biondi-Zoccai G., FeresF,Abizaid A, Costa R.A, Hong M.K, Kim B.K., Jang Y., Kim H.S., Park K.W., Mariani A., Della Riva D., Genereux P., Leon M.B., Bhatt D.L., Bendetto U., Rapezzi C., Stone G.W. Short versus long-term dual antiplatelet therapy after drug-eluting stent implantation. J. Am. Coll. Cardiol. 2015;65(11):1092-102.
  17. Helft G., et al. The OPTIDUAL trial: 12 vs 48 months of clopidogrel after drug-eluting stent placement, European Society of Cardiology 2015 Congress; August 31,2015; London, UK. Abstract 3159.
  18. Bonaca M.P., Bhatt D.L., Cohen M., Steg P.G., Storey R.F., Jensen E.C., Magnani G., Bansilal S., Fish M.P., Im K., Bengtsson O, Oude Ophuis T., Budaj A., Theroux P., Ruda M., Hamm C., Goto S., Spinar J., Nicolau J.C., Kiss R.G., Murphy S.A., Wiviott S.D., Held P., Braunwald E., Sabatine M.S. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 2015;372:1791-800.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies